Scienture (NASDAQ:SCNX) vs. Talphera (NASDAQ:TLPH) Critical Contrast
by Danessa Lincoln · The Markets DailyTalphera (NASDAQ:TLPH – Get Free Report) and Scienture (NASDAQ:SCNX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Insider and Institutional Ownership
37.7% of Talphera shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 21.4% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.25, meaning that its share price is 225% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Talphera and Scienture, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
Talphera currently has a consensus price target of $3.00, suggesting a potential upside of 150.00%. Scienture has a consensus price target of $1.50, suggesting a potential upside of 302.14%. Given Scienture’s higher probable upside, analysts plainly believe Scienture is more favorable than Talphera.
Earnings & Valuation
This table compares Talphera and Scienture”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Talphera | $1,000.00 | 62,287.20 | -$14.29 million | ($0.27) | -4.44 |
| Scienture | $430,000.00 | 35.62 | -$41.51 million | ($2.10) | -0.18 |
Talphera has higher earnings, but lower revenue than Scienture. Talphera is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Talphera and Scienture’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talphera | N/A | -87.28% | -51.36% |
| Scienture | N/A | -53.51% | -42.47% |
Summary
Scienture beats Talphera on 7 of the 13 factors compared between the two stocks.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.